Remarkable therapeutic effects of methylphenidate in periodic limb movement disorder comorbid with excessive daytime sleepiness: a case report
Abstract
Background: Periodic limb movement disorder (PLMD) is a sleep-related movement disorder, which may be accompanied by a complaint of excessive daytime sleepiness (EDS). With this study, we reported a clinical therapy process up to 2.5 years follow-up, exploring the therapeutic effect of a series of medicines in PLMD comorbid EDS.
Case presentation: A 27-year-old woman suffered from EDS for more than 10 years and was then diagnosed with PLMD. Initially, we used levodopa 250 mg per night for 12 weeks, then piribedil 50 mg per night was arranged as the second drug for 12 weeks, and the third drug, pramipexole, was prescribed at a dosage of 0.25 mg per night for 12 weeks, but the EDS was persistent despite the periodic leg movement index (PLMI) returning to normal. Finally, methylphenidate was prescribed at a dosage of 18 mg per day after 4 weeks of washout. Then, the indicators of EDS and PLMD all returned to normal after 6 weeks. A 2.5-year follow-up was scheduled for taking methylphenidate; the symptoms of EDS were steadily well controlled, and PLMI was still kept in the normal range.
Conclusion: This finding suggests that methylphenidate is an optimal therapeutic approach for the management of PLMD comorbid EDS.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.